Alloy Therapeutics Raises $42 Million Series D Financing To Accelerate Discovery Technology Development Across Biologic Modalities
Alloy Therapeutics Raises $42 Million Series D Financing To Accelerate Discovery Technology Development Across Biologic Modalities
10/03/22, 11:01 AM
Location
walthamMoney raised
$42 million
Industry
biotechnology
Round Type
series d
Alloy Therapeutics, a biotechnology ecosystem company, has closed $42 million in Series D financing led by its existing investors 8VC and Mubadala Capital and joined by return investors Thiel Capital, Presight Capital, Founders Fund, and other unnamed family offices and sovereign wealth funds. Alloy will use proceeds from the Series D financing to further support the drug discovery community with new pre-competitive drug discovery technologies in new biologic modalities and new partnership models designed to fuel innovation.
Company Info
Location
275 second ave
waltham, massachusetts, united states
Additional Info
Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. Through a community of partners, we democratize access to tools, technologies, services, and company creation capabilities that are foundational for discovering and developing therapeutic biologics. We provide affordable, non-exclusive access to the entire drug discovery community from academic scientists, small and medium biotech, to the largest biopharma.
Our lead offering, the ATX-Gx™ platform, is a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains.
Founded in 2017 and privately funded by visionary investors, we are headquartered in Boston, MA with European labs in Cambridge, UK.
As a reflection of our relentless commitment to the scientific community, Alloy reinvests 100% of its revenue in innovation and access to innovation.